B
Bull
Bull · 25%IKT
$2.41
情境價格
$2.385
+0.078 (+3.25%)收盤時
Loading chart…
- High
- 2.405
- Open
- 2.310
- VWAP
- 2.35
- Vol
- 523.23K
- Mkt Cap
- 9.89M
- Low
- 2.270
- Amount
- 1.23M
- EV/EBITDA, TTM
- 0.00
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
AI analysis of Inhibikase Therapeutics Inc (IKT)
buyInhibikase Therapeutics Inc (IKT) is a good buy right now due to its recent earnings performance, where it reported a GAAP EPS of -$0.10, beating expectations of -$0.11, indicating improvements in operational efficiency. Additionally, the company has a strong cash position of $170.4 million, which supports ongoing R&D efforts. However, the main risk is its negative earnings trend, with a forward P/E of 0 and a projected loss of -$16.38 million in Q1 2026.
估值指標
The current forward P/E ratio for Inhibikase Therapeutics Inc (IKT) is 0.00, compared to its 5-year average forward P/E of -2.47.
Alphio AI Price Scenarios for IKT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IKT
事件時間軸
資訊
9.007-23NewsfilterInhibikase Receives Orphan Drug Designation
8.507-14seekingalphaInhibikase Therapeutics Sells 25M Shares for $50M
- 9.505-12seekingalpha
Inhibikase Therapeutics Q1 Earnings Beat Expectations
- 5.004-03Newsfilter
Inhibikase Grants Stock Options to New Employees Under Inducement Plan
- 9.503-26seekingalpha
Inhibikase Therapeutics Reports FY 2025 Financial Results
IKT FAQ — answered by Alphio AI
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Inhibikase Therapeutics Inc (IKT) is a good buy right now due to its recent earnings performance, where it reported a GAAP EPS of -$0.10, beating expectations of -$0.11, indicating improvements in operational efficiency. Additionally, the company has a strong cash position of $170.4 million, which supports ongoing R&D efforts. However, the main risk is its negative earnings trend, with a forward P/E of 0 and a projected loss of -$16.38 million in Q1 2026.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。